Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by GraniteShares Advisors LLC

GraniteShares Advisors LLC cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,790 shares of the biopharmaceutical company’s stock after selling 103 shares during the period. GraniteShares Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $534,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Quent Capital LLC lifted its stake in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. KB Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $35,000. Anchor Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $38,000. First Capital Advisors Group LLC. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $80,000. Finally, 1832 Asset Management L.P. acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $88,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $146.60 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $143.52 and a 12 month high of $218.88. The firm has a 50 day moving average of $153.02 and a two-hundred day moving average of $167.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. The business’s revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.68) earnings per share. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets restated an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. HC Wainwright restated a “buy” rating and set a $395.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 5th. Chardan Capital cut their price target on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, February 16th. Royal Bank of Canada reiterated an “outperform” rating and issued a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $216.12.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.